Ruxolitinib improves splenomegaly and other disease-related symptoms in patients with myelofibrosis, but over time, many patients lose this benefit. It is difficult to determine whether this is due to resistance or intolerance to the drug; thus, we have used the more inclusive term of ruxolitinib failure. The survival of patients with myelofibrosis after ruxolitinib failure is poor but varies significantly by the pattern of the failure, underlining the need for a clinically appropriate classification. In this review, we propose diagnostic guidance for early recognition of the pattern of ruxolitinib failure and we recommend treatment options. The most frequent patterns of ruxolitinib failure are loss or failure to obtain a significant reduction in splenomegaly or symptom response, and the development or persistence of clinically significant cytopenias. Ruxolitinib dose modification and other ancillary therapies are sometimes helpful, and splenectomy is a palliative option in selected cases. Stem-cell transplantation is the only curative option for these patterns of failure, but its restricted applicability due to toxicity highlights the importance of ongoing clinical trials in this area. Recent approval of fedratinib by the US Food and Drug Administration provides an alternative option for patients with suboptimal or loss of spleen response. The transformation of myelofibrosis to accelerated or blast phase is an infrequent form of failure with an extremely poor prognosis, whereby patients who are ineligible for transplantation have limited treatment options.

**INTRODUCTION**

Primary myelofibrosis is a rare chronic myeloproliferative neoplasm (MPN) originating from the hematopoietic stem cell. Primary myelofibrosis is characterized by cytopenias, extramedullary hematopoiesis, myelofibrosis, and systemic symptoms resulting from elevated levels of inflammatory and proangiogenic cytokines. A form of myelofibrosis indistinguishable from primary myelofibrosis can occur as part of the natural history of polycythemia vera and essential thrombocythemia, referred to as post-polycythemia vera or postessential thrombocytopenia myelofibrosis. The term myelofibrosis is used in this article to include primary myelofibrosis and myelofibrosis evolved from polycythemia vera or essential thrombocytopenia.

Most patients with myelofibrosis harbor a driver mutation in the **JAK2**, **MPL**, or **CALR** genes causing dysregulation of the JAK-STAT pathway. Discovery of the **JAK2** V617F mutation paved the way for development of small-molecule inhibitors, and the first-in-class JAK inhibitor ruxolitinib was approved for use in myelofibrosis in 2011. At least 10 other JAK inhibitors have entered human clinical trials and fedratinib, pacritinib, and momelotinib have gone through phase III evaluation. Development of several JAK inhibitors has been put on hold due to toxicity concerns or lack of perceived efficacy compared with ruxolitinib. In August 2019, the US Food and Drug Administration approved a second JAK inhibitor, fedratinib, for treatment of patients with myelofibrosis; however, long-term safety data on fedratinib are lacking. Ruxolitinib has the most well-characterized long-term data and safety record.

Ruxolitinib therapy improves splenomegaly- and myelofibrosis-related symptoms irrespective of **JAK2** status. However, its limited anticolonal activity, associated dose-limiting cytopenias, infectious complications, noncurative nature, and substantial rates of discontinuation are major concerns. Weight gain can be an issue for some patients. Patients experience poor outcomes after discontinuation of ruxolitinib therapy. Moreover, treatment options after ruxolitinib failure in myelofibrosis are poorly defined. A pan-Canadian collaboration, Canadian MPN Group (www.mpncanada.com), prepared this consensus document to provide assistance to practicing clinicians.
hematologists and oncologists on the early recognition of ruxolitinib failure and its management.

**RUXOLITINIB FAILURE: RESISTANCE OR INTOLERANCE?**

There are no well-defined criteria for ruxolitinib failure. This is reflected in the varying eligibility criteria for clinical trials investigating the role of fedratinib, pacritinib, and momelotinib as second-line agents in the treatment of patients with myelofibrosis with previous exposure to ruxolitinib. An indirect estimate of ruxolitinib failure may be inferred from treatment discontinuation rates, which vary across reported literature. Mayo Clinic investigators reported a discontinuation rate of 89% at 3 years, compared with 50% at 3 years in the COMFORT trials, which increased to 75% by 5 years. These discrepancies may relate to clinical trial access allowing for a lower threshold to change treatment at suboptimal response, whereas others may continue treatment longer due to lack of effective alternatives. Also, differentiating whether failure of ruxolitinib therapy is due to resistance or intolerance is difficult (eg, cytopenias may require a reduction in dose and may indicate that a patient is intolerant to ruxolitinib). Dose reduction may result in loss of spleen and symptom response indicative of resistance. Unlike chronic myeloid leukemia, there are no molecular correlates to define JAK inhibitor therapy resistance. For these reasons, we prefer to use the broader inclusive term ruxolitinib failure rather than resistance or intolerance (Table 1). Because of overlapping features of ruxolitinib failure, pattern recognition is important for adequate treatment of these patients.

**RESPONSE ASSESSMENT TO JAK INHIBITOR THERAPY IN ROUTINE CLINICAL PRACTICE**

International Working Group-Myeloproliferative Neoplasms Research and Treatment criteria are used frequently for response assessment in myelofibrosis clinical trials; however, these criteria are not used in clinical practice to assess ruxolitinib response, according to our survey of Canadian hematologists. Because complete or partial remissions are not seen with current JAK inhibitor therapy, response in routine practice is judged by the indication for therapy, such as symptomatic splenomegaly and/or myelofibrosis-associated symptoms balanced with hematologic toxicity. Volumetric assessment of spleen by magnetic resonance imaging or computed tomography scan has been the primary end point of several clinical trials but is not used in routine clinical care in Canada; splenomegaly is monitored by physical examination, and consistent spleen examination with measurement is necessary. Ultrasound is used often in patients with a difficult physical examination. Monitoring of myelofibrosis symptom response is recommended using a standardized instrument such as the MPN-10 or MPN-SAF, and evaluation of performance status. The use of these instruments is variable outside clinical trials, and integration into routine workflow is suggested.

**PATTERNS OF RUXOLITINIB FAILURE**

Suboptimal Spleen or Symptom Response or Loss of Response

Splenomegaly is found in 90% of patients with myelofibrosis at presentation. In clinical trials, a significant

---

**TABLE 1.** Canadian MPN Group’s Operational Definition of Ruxolitinib Failure

| Pattern of JAK Inhibitor Therapy Failure | Definition | Expected Survival (months) | Optimization Strategy for Ruxolitinib* |
|-----------------------------------------|------------|-----------------------------|---------------------------------------|
| Suboptimal spleen response              | <25% reduction in palpable spleen length after at least 3 months of optimally dosed JAK inhibitor therapy | 14-18<sup>13,15</sup> | Increase JAK inhibitor dose depending on Hb and platelet counts |
| Loss of spleen response                 | ≥50% increase in spleen length from best response | 14-18<sup>13,15</sup> | Increase JAK inhibitor dose depending on Hb and platelet counts |
| Transfusion-dependent anemia           | ≥4 units of RBC transfusions in 8 weeks occurring ≥6 months from ruxolitinib treatment | 8<sup>12-16</sup> | Decrease JAK inhibitor dose |
| Severe thrombocytopenia                 | Unable to maintain unsupported platelet count >35-50×10<sup>9</sup>/L in patients receiving anticoagulation medication; and >25 ×10<sup>9</sup>/L in patients without anticoagulation | 8<sup>12-15</sup> | Decrease JAK inhibitor dose |
| Transformation to AP/BP                | 4-6<sup>41-44</sup> | Continue JAK inhibitor therapy if required for splenomegaly and symptoms, dose adjustment depending on Hb and platelet counts |
| Second cancers                         | Variable   | Case-by-case discussion of JAK inhibitor therapy discontinuation |
| Infectious complications               | Variable   | Consider if there would be benefit from adding prophylactic strategies to prevent recurrent infections |

Abbreviations: AML, acute myeloid leukemia; AP, accelerated phase; BP, blast phase; Hb, hemoglobin; MPN, myeloproliferative neoplasms.

*If dose-optimization strategy does not resolve the issue, consider an additional treatment strategy, per Figure 1.
Management of Ruxolitinib Failure in Myelofibrosis

spleen response was defined as a ≥ 35% reduction in spleen volume based on magnetic resonance imaging or computed tomography, which corresponds to a 50% reduction in palpable splenomegaly. This end point was arbitrarily defined and even patients with less reduction in spleen size derive clinical benefit. There is agreement among Canadian physicians to define ruxolitinib failure as suboptimal spleen response, with a < 25% reduction in palpable baseline spleen length or the persistence of symptomatic splenomegaly.

In patients who once achieved a spleen response with ruxolitinib, we define a loss of response as > 50% increase in spleen length from best-achieved response. In the setting of suboptimal response or loss of response, a careful review of dosing, compliance, and drug-drug interactions is recommended. If blood cell counts permit, the dose of ruxolitinib should be increased. Retrospective case series have shown a rechallenge with ruxolitinib after a period of interruption may result in regaining spleen response. However, these responses are not durable in a large proportion of patients and this strategy is not recommended in routine clinical practice.

Several single and multicenter retrospective studies have indicated median survival of 14 to 18 months in patients with suboptimal or loss of spleen response to JAK inhibitor therapy. Given the poor survival, consideration of hematopoietic cell transplantation (HCT) is recommended for transplantation-eligible patients (Fig 1A). We recommend that all reasonably fit patients in the transplantation age group with suitable donors should be considered for HCT. For those not eligible, enrolment into a clinical trial is strongly suggested. Clinical trial strategies include alternative JAK inhibitor therapy, combination therapy or novel agents targeting pathways other than JAK-STAT. Recently, the Food and Drug Administration approved a second JAK inhibitor, fedratinib, for patients with myelofibrosis. JAKARTA-2, a single-arm, phase II trial, illustrated 53% of patients who had “ruxolitinib resistance” achieved a significant spleen response (≥ 35%) with fedratinib. Fedratinib is not currently available in routine clinical practice outside of the United States. Several ongoing trials (FREEDOM 1 and FREEDOM 2) are further evaluating the long-term safety and efficacy of fedratinib and will enhance our understanding of the role of fedratinib in patients with ruxolitinib failure. Other salvage therapies available in routine practice for symptomatic splenomegaly include hydroxyurea, lenalidomide, thalidomide, interferon, prednisone, and danazol. However, the exact benefit of these treatment strategies is unclear.

Splenectomy is a treatment option for drug-refractory splenomegaly but carries substantial risk, with 31% and 9% morbidity and mortality rates, respectively. The main complications are bleeding, infection, and thrombosis. Risk factors influencing survival post-splenectomy derived from 120 patients with myelofibrosis (namely, age > 65 years, transfusion requiring anemia, leukocyte count > 25 × 10⁹/L, and circulating blasts > 5%) were incorporated into a scoring system, which may serve as a tool for patient selection. Splenic irradiation can be a potential alternative for patients who are considered poor candidates for splenectomy and for end-stage symptom control purposes. The effect of splenic radiation is of short duration; severe and prolonged cytopenias remain a major clinical issue. Our approach to patients with suboptimal or loss of response to ruxolitinib therapy is summarized in Figure 1A.

Dose-Limiting Cytopenias: Anemia

Anemia is a known on-target effect of ruxolitinib. In the COMFORT trials, anemia was observed more frequently in the ruxolitinib arms. Anemia is also a major feature of progressive myelofibrosis. Given that there is no biomarker to differentiate between anemia resulting from ruxolitinib compared with anemia related to underlying myelofibrosis, clinical judgement is required. Timing of anemia and other associated symptoms helps differentiate between drug-induced versus disease-related anemia. Development of anemia in the first 12 weeks of ruxolitinib treatment is expected, and a new baseline is usually established by week 24. This anemia is self-limited and dose dependent. However, worsening anemia beyond the first 6 months of treatment may be unrelated to medication. Anemia occurring as a result of disease progression is often accompanied by an increase in myelofibrosis symptoms or splenomegaly. There was significant difference of opinion among the Canadian hematologists surveyed regarding occurrence of anemia as a marker of ruxolitinib failure. There was broader consensus that in a patient who was transfusion independent before beginning ruxolitinib treatment, transfusion-requiring anemia after 24 weeks of ruxolitinib therapy in the absence of bleeding or other causes should be considered indicative of ruxolitinib failure. Different definitions of transfusion dependence were considered, as reported in the MPN literature.

A study from the Princess Margaret Cancer Centre showed that transfusion-requiring anemia is associated with poor outcome irrespective of the number of transfusions, and that patients with myelofibrosis who become transfusion dependent while receiving JAK inhibitor therapy have a median survival of 8 months. We define transfusion dependence as at least four units of packed RBCs over 8 weeks in the absence of active bleeding or other causes. Outside the setting of clinical trials, erythropoietin-stimulating agents (ESAs), should be considered in a transfusion-dependent patient who is otherwise doing well on ruxolitinib. In the COMFORT trials, ESA use was discouraged because ESAs can activate the JAK-STAT pathway, potentially resulting in increased splenomegaly. A small number of patients in the COMFORT-II trial did receive both an ESA and ruxolitinib with some benefit and no compromise in ruxolitinib efficacy. In patients who have a serum erythropoietin level < 500 IU/L, a 3-month trial of
FIG 1. Management strategies for ruxolitinib failure. (A) Suboptimal or loss of spleen response. (B) New-onset transfusion-dependent anemia. (C) Severe thrombocytopenia. (D) Progression to accelerated phase/blast phase. (*) Fedratinib is approved by the US Food and Drug Administration; approval is pending in other jurisdictions. AML, acute myeloid leukemia; AP, accelerated phase; BP, blast phase; EPO, erythropoietin; ESA, erythropoietin-stimulating agent; HCT, hematopoietic cell transplantation.
**C**

- Severe Thrombocytopenia
  - Decrease ruxolitinib dose
    - No success
      - Transplant eligible?
        - Yes
          - Consider HCT
        - No
          - Availability of clinical trial
            - Yes
              - Clinical trial
            - No
              - Supportive therapy: consider tranexamic acid
                - Consider early splenectomy

**D**

- Progression to AP/BP
  - Transplant eligible?
    - Yes
      - Donor readily available?
        - Yes
          - AML-type induction therapy
        - No
          - B blasts < 5%?
            - Yes
              - Proceed to HCT
            - No
              - Consider clinical trial
    - No
      - Progressive leukocytosis
        - Yes
          - Consider cytoreduction
        - No
          - Review molecular profiling
            - Yes
              - Targeted therapy or clinical trial available?
                - Yes
                  - Use targeted therapy or enroll in clinical trial
                - No
                  - Consider hypomethylating therapy
            - No
              - Use targeted therapy or enroll in clinical trial

**FIG 1.** (Continued).
ESA is suggested. Alternatively, one can decrease the dose of ruxolitinib (Table 1; Fig 1B); however, this can result in a decrease in efficacy in symptoms and spleen response. If a minimum efficacious dose of ruxolitinib cannot be maintained, an alternative treatment strategy must be considered, including HCT or clinical trials (Fig 1B).

Other agents such as danazol,34 lenalidomide35 and thalidomide36 have been used in combination with ruxolitinib. The studies reporting this use were limited by small sample size for any definitive conclusions to be drawn. Another JAK inhibitor, momelotinib, has shown efficacy at reducing transfusion requirements.37,38 In the SIMPLIFY 2 study, researchers evaluated momelotinib compared with best available therapy in patients previously exposed to ruxolitinib.6 Although the primary end point of spleen reduction was not met, 43% of patients achieved transfusion independence at week 24 compared with 21% of those receiving best available therapy. An upcoming clinical trial will further evaluate the role of momelotinib in patients with myelofibrosis who have transfusion-dependent anemia. Splenectomy may be considered as an alternative for drug-refractory anemia.29

Dose-Limiting Cytopenias: Thrombocytopenia

Thrombocytopenia is a dose-limiting toxicity of ruxolitinib. Patients with myelofibrosis with severe thrombocytopenia are a particularly challenging subgroup. In a Spanish registry, up to 7.2% of patients with myelofibrosis had severe thrombocytopenia (platelet count < 50 × 10^9/L) at diagnosis.39 Compared with the general myelofibrosis population, patients with severe thrombocytopenia had higher symptom burden, and higher incidence of bleeding, leukemic transformation, and death, with a median survival of 2.2 years. HCT should be considered earlier in these patients. To our knowledge, no prospective studies have been done with ruxolitinib in patients with severe thrombocytopenia (platelet count < 50 × 10^9/L), and clinical experience with JAK inhibitor therapy in patients with severe thrombocytopenia is limited. A lower starting dose followed by gradual upward titration is recommended for patients with platelet count < 100 × 10^9/L.

Severe thrombocytopenia emerging while a patient is receiving a stable dose of ruxolitinib suggests disease progression and is associated with poor survival, ranging from 6 to 9 months.12,13 Dose reduction or alternative therapy should be considered, though additional treatment options are limited, given platelet count restrictions in many clinical trials.

Strategies such as low-dose corticosteroids, danazol, and immunomodulators have limited efficacy data. In selected patients with drug-refractory thrombocytopenia, early consideration of splenectomy is suggested (Fig 1C).29 Suggested platelet transfusion thresholds vary depending on anticoagulation needs (Table 1), and supportive care including tranexamic acid may be required to mitigate the risk of serious bleeding.

Transformation to Accelerated or Blast Phase

A study of 1,038 patients with myelofibrosis reported that patients with a blast percentage ≥ 4% in peripheral blood (PB) or ≥ 5% in bone marrow had poor survival similar to patients with disease in accelerated phase (AP) with blast percentage between 10% and 19%.60 No consensus was reached among the Canadian MPN group for criteria defining the magnitude of change in the PB blasts warranting treatment re-evaluation. The International Working Group-Myeloproliferative Neoplasms Research and Treatment criteria for “progressive disease” includes “bone marrow or peripheral blood blasts ≥ 20% also known as blast phase (BP), for at least 2 weeks,” but does not include AP in its definition.22 Patients with myelofibrosis with PB blasts > 10% have been excluded from prospective JAK inhibitor studies. We suggest that transformation to both AP and BP constitutes JAK inhibitor therapy failure and that these patients should be treated similarly. Median survival of patients with myelofibrosis with AP/BP is 4 to 6 months41-45 and only select patients may proceed to HCT.41,43 Before HCT, either intensive chemotherapy or hypomethylating agents may offer temporary disease control (Fig 1D). Intensive AML-type chemotherapy in itself has limited value unless consolidated with HCT.41,43,46 We strongly recommend participation in clinical trials (Fig 1D). Given emerging therapies, a targeted myeloid gene panel analysis to identify targetable mutations should be considered.47

Secondary Cancers

The incidence of secondary malignancies in patients treated with ruxolitinib is likely attributable to the immunosuppressive effects of ruxolitinib; the JAK-STAT pathway is involved in activation of many cytokines involved in anticaner surveillance. Although nonmelanoma skin cancers have been reported in patients with MPN treated with ruxolitinib,19 the number of other nonhematologic, nonskin cancers is too small to determine if there is an increased risk with ruxolitinib, because of confounding factors. There is a clear increase in lymphoma in patients with MPN at baseline, which must be acknowledged in determining if ruxolitinib enhances this risk. For example, a relative increase in aggressive B-cell lymphoma of 5.8% to 9.7% of patients treated with ruxolitinib compared with 0.36% to 0.54% in control patients was reported in a study from two European centers.68 By contrast, an extensive American registry study did not confirm this increase in lymphoma in patients treated with ruxolitinib compared with patients in the pre-ruxolitinib era.49 We recommend that in patients with myelofibrosis treated with ruxolitinib in whom localized basal or squamous cell carcinoma of skin develops, treatment with ruxolitinib can be continued unless multiply recurrent or aggressive. Clinically aggressive secondary cancers should be
TABLE 2. Useful Practice Points in Managing Ruxolitinib Failure

| Serial No. | Practice Point |
|------------|----------------|
| 1          | Dose optimization of ruxolitinib therapy should be attempted in patients with myelofibrosis whose disease has suboptimal response or in whom severe cytopenias develop. |
| 2          | Survival of patients with myelofibrosis after ruxolitinib therapy failure is poor and variable, depending on the cause of failure (Table 1). These patients should be clinically evaluated at an expert center if failure is suspected. |
| 3          | HCT should be considered in cases of ruxolitinib failure for transplant-eligible patients with adequate performance status. Consider earlier HCT referral in patients at high-risk for ruxolitinib failure (eg, high-risk DIPSS, RBC transfusion-dependent before ruxolitinib treatment, high-risk mutations, such as ASXL1 and EZH2). |
| 4          | Patients not eligible for transplant should be offered enrollment in clinical trials. |
| 5          | For switching patients from ruxolitinib to alternative therapy, gradual taper should be considered. Sudden discontinuation can cause withdrawal symptoms. |
| 6          | For symptomatic refractory splenomegaly, transfusion-dependent anemia, and severe thrombocytopenia, splenectomy is a useful palliative option for symptom control. |

Abbreviations: HCT, hematopoietic cell transplant; DIPSS, Dynamic International Prognostic Stratification System.

There are no guidelines on the use of anti-infection prophylactic strategies in patients with myelofibrosis requiring ruxolitinib therapy. Various Canadian MPN centers practice vaccination with Shingrix (GlaxoSmithKline, Brentford, United Kingdom) before initiating ruxolitinib therapy. We recommend treatment of active infection, followed by the appropriate prophylactic therapy for secondary prevention (eg, suppressive antiviral therapy). Before treatment, patients should receive hepatitis and HIV screening and those from endemic areas and/or with prior tuberculosis exposure or contacts be considered for tuberculosis screening. Most common infections in patients receiving ruxolitinib therapy, such as herpes or urinary tract infection, do not necessitate stopping the treatment. Serious, life-threatening infections will merit careful consideration of risks and benefits of continuing ruxolitinib therapy on a case-by-case basis.

SWITCHING FROM RUXOLITINIB THERAPY TO ALTERNATIVE THERAPY

Discontinuation of ruxolitinib will be required in some patients needing alternative therapies such as HCT, a second-line JAK inhibitor, or participation in another clinical trial. We recommend gradual taper of ruxolitinib, given that sudden discontinuation of ruxolitinib can cause withdrawal symptoms. For transplantation patients, we recommend a slow taper over 5 days and that the last dose of ruxolitinib be taken 1 day before conditioning therapy. For other patients, we recommend decreasing the dose by 5 mg twice daily per week with close monitoring of withdrawal or return of myelofibrosis-related symptoms. A short course of steroids can be helpful until a definitive alternative treatment is started.

In conclusion, the outcome of patients in whom ruxolitinib treatment fails is heterogeneous and depends on the cause of failure. It is important to recognize the pattern of ruxolitinib failure, because treatment will depend predominantly on the cause. Patients with high-risk Dynamic International Prognostic Scoring System scores, transfusion requiring anemia before beginning ruxolitinib therapy, and those with high-risk mutations such as ASXL1 and EZH2 are at higher risk of ruxolitinib failure and HCT should be considered earlier (Table 2). Several alternative therapeutic strategies are being actively investigated and participation in clinical trials is strongly recommended to make further progress in this area.

AFFILIATIONS

1Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada
2Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada
3St Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
4Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada
5Dalhousie University, Halifax, Nova Scotia, Canada
6Memorial University of Newfoundland, St John’s, Newfoundland and Labrador, Canada
7Windsor Regional Cancer Program, Windsor, Ontario, Canada
8Jewish General Hospital, Montreal, Quebec, Canada

*Jewish General Hospital, Montreal, Quebec, Canada
©2023 ASCO, All Rights Reserved. Copyright 2023 American Society for Clinical Oncology.
CORRESPONDING AUTHOR
Vikas Gupta, MD, Princess Margaret Cancer Centre, 700 University Ave, 6-326, Toronto, Ontario, Canada, M5G 1Z5; e-mail: vikas.gupta@uhn.ca

SUPPORT
Supported by the Princess Margaret Cancer Foundation and Elizabeth and Tony Comper Foundation grants (V.G.).

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if applicable) are available with this article at DOI https://doi.org/10.1200/JOP.19.00506.

REFERENCES
1. Harrison C, Kiladjian JJ, Al-Ali HK, et al: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787-798, 2012
2. Verstovsek S, Mesa RA, Gotlib J, et al: A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799-807, 2012
3. Devlin R, Gupta V: Myelofibrosis: To transplant or not to transplant? Hematology (Am Soc Hematol Educ Program) 2016;543-551, 2016
4. Pardanani A, Harrison C, Cortes JE, et al: Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. JAMA Oncol 1:643-651, 2015
5. Mesa RA, Kiladjian JJ, Catalano JV, et al: SIMEPLYF-1: A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naive patients with myelofibrosis. J Clin Oncol 35:3844-3850, 2017
6. Harrison CN, Vannucchi AM, Platzbecker U, et al: Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPPLYF-1): A randomised, open-label, phase 3 trial. Lancet Haematol 5:e73-e81, 2018
7. Mesa RA, Vannucchi AM, Mead A, et al: Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSISIT-1): An international, randomised, phase 3 trial. Lancet Haematol 4:e225-e236, 2017
8. Mascarenhas J, Hoffman R, Talpaz M, et al: Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial. JAMA Oncol 4:652-659, 2018
9. Harrison CN, Vannucchi AM, Kiladjian JJ, et al: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30:1701-1707, 2016
10. Cervantes F, Vannucchi AM, Kiladjian JJ, et al: Three-year efficacy, safety, and survival findings from COMFORT-I, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122:4047-4053, 2013
11. Verstovsek S, Gotlib J, Mesa RA, et al: Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol 10:156, 2017
12. Newberry KJ, Patel K, Masarova L, et al: Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood 130:1125-1131, 2017
13. McNamara C, Spiegel J, Xu W, et al: Long-term follow up of JAK inhibitor (JAKi) treated patients with myelofibrosis: Impact of molecular enhanced integrated scoring systems and type of JAKi therapy failure on survival (abstract no. PS1460). Presented at European Hematology Association 24th Congress, Amsterdam, the Netherlands, June 13-16, 2019
14. Kuykendall AT, Shah S, Talati C, et al: Between a rux and a hard place: Evaluating salvage treatment and outcomes in myelofibrosis. JOP 15:568-575, 2019
15. Palandri F, Nicolosi M, Palumbo G, et al: Duability of spleen response may affect outcome of ruxolitinib-treated patients with myelofibrosis: Results from a single-arm, open-label study. Presented at European Hematology Association 24th Congress, Amsterdam, the Netherlands, June 13-16, 2019
16. Harrison CN, Schapa N, Vannucchi AM, et al: Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol 4:e317-e324, 2017
17. Tefferi A, Lizow MR, Pardanani A: Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 365:1455-1457, 2011
18. Verstovsek S, Mesa RA, Gotlib J, et al: Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: Results of a median 3-year follow-up of COMFORT-I. Hematologica 100:479-488, 2015
19. Verstovsek S, Mesa RA, Gotlib J, et al: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-Year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10:55, 2017
20. Harrison CN, Vannucchi AM, Kiladjian JJ, et al: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (Erratum). Leukemia 31:775, 2017
21. Tefferi A, Barosi G, Mesa RA, et al: International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108:1497-1503, 2006
22. Tefferi A, Cervantes F, Mesa R, et al: Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122:1395-1398, 2013
23. Mesa R, Jamieson C, Bhatia R, et al: Myeloproliferative neoplasms, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 14:1572-1611, 2016
24. Cervantes F, Dupriez B, Pereira A, et al: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895-2901, 2009
25. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010
26. Mesa RA, Gotlib J, Gupta V, et al: Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 31:1285-1292, 2013

AUTHOR CONTRIBUTIONS
Conception and design: Vikas Gupta, Sonia Cerquozzi, Lynda Foltz, Christopher Hallis, Rebecca Devlin, Shireen Sirhan, Brian Leber
Collection and assembly of data: Vikas Gupta, Christopher Hallis, Rebecca Devlin, Mahmoud Elsawy, Caroline McNamar
Data analysis and interpretation: Vikas Gupta, Christopher Hallis, Mahmoud Elsawy, Kuljit Grewal, Caroline Hamm, Caroline McNamar
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
27. Gerds A, Su D, Martynova A, et al: Ruxolitinib rechallenge can improve constitutional symptoms and splenomegaly in patients with myelofibrosis: A case series. Clin Lymphoma Myeloma Leuk 18:e463-e468, 2018

28. Tefferi A, Mesa RA, Nagorney DM, et al: Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients. Blood 95: 2226-2233, 2000

29. Tefferi A, Mudireddy M, Gangat N, et al: Risk factors and a prognostic model for post-splenectomy survival in myelofibrosis. Am J Hematol 92:1187-1192, 2017

30. Elliott MA, Chen MG, Silverstein MN, et al: Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103:505-511, 1998

31. Gale RP, Banos G, Barbui T, et al: What are RBC-transfusion-dependence and -independence? Leuk Res 35:8-11, 2011

32. Barszcz J, Panzarella T, Lau A, et al: Effect of red blood cell transfusion dependence on the natural history of myeloproliferative neoplasm-associated myelofibrosis. Clin Lymphoma Myeloma Leuk 15:e151-e156, 2015

33. McMullin MF, Harrison CN, Niederwieser D, et al: The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: An open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol 4:26, 2015

34. Gowin K, Kosiorek H, Dueck A, et al: Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leuk Res 60: 31-35, 2017

35. Nave D, Cortes JE, Jabbour E, et al: Ruxolitinib and lenalidomide as a combination therapy for patients with myelofibrosis. Blood 124:1831, 2014

36. Rampal RK, Verstovsek S, Devlin SM, et al: Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: Initial results of a phase II study. Blood 132:354, 2018 (suppl 1)

37. Pardanani A, Gottlieb J, Roberts AW, et al: Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Leukemia 32:1035-1038, 2018

38. Gupta V, Mesa RA, Deininger MW, et al: A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica 102:94-102, 2017

39. Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, et al: Clinical characteristics, prognosis and treatment of myelofibrosis. Br J Haematol 181:397-400, 2018

40. Masarova L, Bose P, Newberry K, et al: Correlation between blast percentage in myelofibrosis and outcomes: A single-center experience. J Clin Oncol 35: e18562, 2017 (15_suppl)

41. Kennedy JA, Atenafu EG, Messner HA, et al: Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 121:2725-2733, 2013

42. Tefferi A, Mudireddy M, Mannelli F, et al: Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia 32:1200-1210, 2018

43. Tan CS, Nussenzweig RM, Popat U, et al: The natural history and treatment outcome of blast phase BCR-ABL1 myeloproliferative neoplasms. Blood 112: 1555-1557, 2008

44. Mesa RA, Li CY, Ketterling RP, et al: Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 105:973-977, 2005

45. McNamara C, Kennedy J, Panzarella T, et al: No improvement in survival over time for Philadelphia-negative patients who transform to accelerated or blast phase. European Hematology Association 21st Annual Congress, Copenhagen, Denmark, June 9-12, 2017

46. McNamara CJ, Panzarella T, Kennedy JA, et al: The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes. Blood Adv 2:2658-2733, 2018

47. Odenike O: How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 132:2339-2350, 2018

48. Porpacey E, Tripolt S, Hoelbl-Kovacic A, et al: Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood 132:694-706, 2018

49. Pemmaraju N, Kantarjian H, Nastoupil L, et al: Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood 133:2348-2351, 2019

50. Heine A, Brossart P, Wolf D: Ruxolitinib is a potent immunosuppressive compound: Is it time for anti-infective prophylaxis? Blood 122:3843-3844, 2013

51. Lussana F, Cattaneo M, Rambaldi A, et al: Ruxolitinib-associated infections: A systematic review and meta-analysis. Am J Hematol 93:339-347, 2018

52. Al-Ali HK, Griesshammer M, le Coutre P, et al: Safety and efficacy of ruxolitinib in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant 22:432-440, 2016

53. Shanavas M, Popat U, Michaelis LC, et al: Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors. Biol Blood Marrow Transplant 25:256-264, 2019

54. Gupta V, Kosiorek HE, Mead A, et al: Ruxolitinib therapy followed by reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant 32:1035-1038, 2018

55. Patel KP, Newberry KJ, Luthra R, et al: Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood 126:790-797, 2015

56. Spiegel JY, McNamara C, Kennedy JA, et al: Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Adv 1:1729-1738, 2017
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Vikas Gupta
Honoraria: Novartis, Incyte, Sierra Oncology, Celgene
Consulting or Advisory Role: Novartis, Sierra Oncology, Celgene
Research Funding: Novartis (Inst)

Sonia Cerquozzi
Honoraria: Novartis, Pfizer, Celgene
Consulting or Advisory Role: Novartis, Celgene
Travel, Accommodations, Expenses: Novartis, Celgene

Lynda Foltz
Employment: Amgen (I)
Stock and Other Ownership Interests: Amgen (I)
Honoraria: Novartis
Consulting or Advisory Role: Novartis, Celgene
Research Funding: Celgene (Inst), Novartis (Inst), Incyte (Inst), Constellation Pharmaceuticals (Inst)

Christopher Hillis
Honoraria: Novartis, Celgene
Travel, Accommodations, Expenses: Novartis

Mahmoud Elsawy
Honoraria: Celgene, Kite/Gilead, Pfizer, Roche, Jazz Pharmaceuticals, Novartis, Janssen-Cilag
Consulting or Advisory Role: Kite/Gilead, Novartis, Celgene, Roche, Jazz Pharmaceuticals, Pfizer

Kuljit Grewal
Honoraria: Celgene, Novartis
Consulting or Advisory Role: Celgene, Novartis
Travel, Accommodations, Expenses: Celgene, Novartis

Caroline Hamm
Consulting or Advisory Role: Amgen, Novartis, Paladin

Caroline McNamara
Honoraria: Novartis

Shireen Sirhan
Honoraria: Novartis, Celgene
Consulting or Advisory Role: Novartis, Celgene
Speakers’ Bureau: Novartis
Research Funding: Novartis
Travel, Accommodations, Expenses: Novartis

Brian Leber
Honoraria: AbbVie, Novartis Canada Pharmaceuticals, Pfizer, Celgene, Amgen, Astellas Pharma, Janssen Oncology, Otsuka, Jazz Pharmaceuticals
Expert Testimony: Novartis Canada Pharmaceuticals, Pfizer

No other potential conflicts of interest were reported.